<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025762</url>
  </required_header>
  <id_info>
    <org_study_id>DAN06</org_study_id>
    <nct_id>NCT04025762</nct_id>
  </id_info>
  <brief_title>24/7 Closed-loop in Older Subjects With Type 1 Diabetes</brief_title>
  <acronym>DAN06</acronym>
  <official_title>An Open-label, Multi-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of 16 Week Day and Night Automated Closed-loop Glucose Control Under Free Living Conditions Compared to Sensor Augmented Insulin Pump Therapy in Older Adults With Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this open-label, multi-centre, randomised, crossover design study is to&#xD;
      determine whether automated day and night closed-loop insulin delivery for 16 weeks under&#xD;
      free living conditions is safer and more efficacious compared to sensor augmented insulin&#xD;
      pump therapy in older adults with type 1 diabetes. The primary outcome is time spent in&#xD;
      target range between 3.9 and 10.0 mmol/L (70 and 180 mg/dl) as recorded by CGM. Secondary&#xD;
      outcomes are the HbA1c, time spent with glucose levels above and below target, as recorded by&#xD;
      CGM, and other CGM-based metrics. Measures of human factor assessments, cardiac arrhythmias&#xD;
      and objective sleep quality assessment will also be evaluated in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No study thus far has specifically evaluated use of closed-loop insulin delivery in older&#xD;
      adults with type 1 diabetes. During our previous closed-loop studies, if there is a&#xD;
      communication failure between the algorithm device and the insulin pump, the pump is set to&#xD;
      deliver pre-programmed basal insulin rates after about 30 to 60 minutes.The main objective of&#xD;
      this study is to determine whether automated day and night closed-loop insulin delivery for&#xD;
      16 weeks under free living conditions is safer and more efficacious compared to sensor&#xD;
      augmented insulin pump therapy in older adults with type 1 diabetes.&#xD;
&#xD;
      This is an open-label, multi-centre, randomised, crossover design study, involving a 4-6 week&#xD;
      run-in period, followed by two 4 months study periods during which glucose levels will be&#xD;
      controlled either by an automated closed-loop system or by sensor-augmented pump therapy in&#xD;
      random order. A total of up to 42 adults (aiming for 36 completed subjects) aged 60 years and&#xD;
      older with T1D on insulin pump therapy will be recruited through diabetes clinics and other&#xD;
      established methods in participating centres. Subjects who drop out of the study within the&#xD;
      first 6 weeks of the first intervention period will be replaced.&#xD;
&#xD;
      Subjects will receive appropriate training in the safe use of closed-loop insulin delivery&#xD;
      system. Subjects will have regular contact with the study team during the home study phase&#xD;
      including 24/7 telephone support.&#xD;
&#xD;
      The primary outcome is time spent in target range between 3.9 and 10.0 mmol/L (70 and&#xD;
      180mg/dl) as recorded by CGM. Secondary outcomes are the HbA1c, time spent with glucose&#xD;
      levels above and below target, as recorded by CGM, and other CGM-based metrics. Measures of&#xD;
      human factor assessments, cardiac arrhythmia and objective sleep quality assessment will also&#xD;
      be evaluated in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">August 20, 2021</completion_date>
  <primary_completion_date type="Actual">August 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>An open-label, multi-centre randomised, two-period crossover study comparing day and night automated closed-loop glucose control with sensor-augmented pump therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time spent in the target sensor glucose range</measure>
    <time_frame>16 weeks</time_frame>
    <description>Time spent in the target glucose range from 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on continuous glucose monitoring (CGM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c at the end of treatment period</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent below target glucose (3.9mmol/l) (70mg/dl) based on CGM</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent above target glucose (10.0 mmol/l) (180 mg/dl) based on CGM</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average, standard deviation, and coefficient of variation of CGM glucose levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time with glucose levels &lt; 3.5 mmol/l (63mg/dl) and &lt; 3.0 mmol/l (54mg/dl) based on CGM</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time with glucose levels in the significant hyperglycaemia (glucose levels &gt; 16.7 mmol/l) (300mg/dl)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total, basal and bolus insulin dose</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Utility evaluation</measure>
    <time_frame>16 weeks</time_frame>
    <description>The frequency and duration of use of the closed-loop system at home.</description>
  </other_outcome>
  <other_outcome>
    <measure>Human Factor assessment</measure>
    <time_frame>30 minutes</time_frame>
    <description>Cognitive, emotional, and behavioural characteristics of participating subjects and family members and their response to the closed-loop system and clinical trial will be assessed using validated surveys and focus groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac arrythmia analysis</measure>
    <time_frame>5-7 days</time_frame>
    <description>Holter monitor data at the fourth month in the two treatment groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep quality assessment</measure>
    <time_frame>14 days</time_frame>
    <description>Sleep quality assessment using data collected by Actiwatch</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <condition>Arrythmia</condition>
  <arm_group>
    <arm_group_label>Day and night hybrid closed loop control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The day and night hybrid closed-loop system (CamAPS FX) will consist of:&#xD;
Dana RS insulin pump (Sooil)&#xD;
G6 real-time CGM sensor (Dexcom)&#xD;
An unlocked android smartphone hosting the CamAPS FX app with Cambridge control algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensor augmented pump therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator will consist of Dana RS insulin pump (Sooil) and G6 real-time CGM sensor (Dexcom)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid closed-loop system (CamAPS FX)</intervention_name>
    <description>Hybrid closed-loop system</description>
    <arm_group_label>Day and night hybrid closed loop control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sensor augmented pump therapy</intervention_name>
    <description>Sensor augmented pump therapy</description>
    <arm_group_label>Sensor augmented pump therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 60 years and above&#xD;
&#xD;
          2. Type 1 diabetes as defined by WHO for at least 1 year or confirmed C-peptide negative&#xD;
&#xD;
          3. On insulin pump for at least 3 months with good knowledge of insulin self-adjustment&#xD;
&#xD;
          4. Treated with one of the U-100 rapid acting insulin analogues only (insulin Aspart,&#xD;
             Lispro, Faster insulin Aspart but not Glulisine)&#xD;
&#xD;
          5. Willing to perform regular capillary blood glucose monitoring&#xD;
&#xD;
          6. HbA1c â‰¤ 10% (86 mmol/mmol) based on analysis from central laboratory or equivalent&#xD;
&#xD;
          7. Literate in English&#xD;
&#xD;
          8. Having a care partner who is aware of the subject's location and is trained to&#xD;
             administer intramuscular glucagon and able to seek emergency assistance&#xD;
&#xD;
          9. Willing to wear closed-loop system at home and at work place&#xD;
&#xD;
         10. Willing to follow study specific instructions&#xD;
&#xD;
         11. Willing to upload pump and CGM data at regular intervals&#xD;
&#xD;
         12. Has access to WiFi&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-type 1 diabetes mellitus&#xD;
&#xD;
          2. Use of a closed-loop system within the last 30 days&#xD;
&#xD;
          3. Any other physical or psychological disease or condition likely to interfere with the&#xD;
             normal conduct of the study and interpretation of the study results&#xD;
&#xD;
          4. Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs) in&#xD;
             the 3 months prior to enrolment or any use of SGLT2 inhibitors&#xD;
&#xD;
          5. Untreated coeliac disease, adrenal insufficiency or hypothyroidism&#xD;
&#xD;
          6. Known or suspected allergy against insulin&#xD;
&#xD;
          7. More than one episodes of severe hypoglycaemia as defined by American Diabetes&#xD;
             Association in preceding 6 months&#xD;
&#xD;
          8. Random C-peptide &gt; 200pmol/l with concomitant plasma glucose &gt;4 mmol/l (72 mg/dl)&#xD;
&#xD;
          9. Lack of reliable telephone facility for contact&#xD;
&#xD;
         10. Total daily insulin dose &gt;/= 2 IU/kg/day&#xD;
&#xD;
         11. Total daily insulin dose &lt; 15 IU/day&#xD;
&#xD;
         12. Severe visual impairment&#xD;
&#xD;
         13. Severe hearing impairment&#xD;
&#xD;
         14. Medically documented allergy towards the adhesive (glue) of plasters or unable to&#xD;
             tolerate tape adhesive in the area of sensor placement&#xD;
&#xD;
         15. Serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) located at&#xD;
             places of the body, which could potentially be used for localisation of the glucose&#xD;
             sensor)&#xD;
&#xD;
         16. Subject is currently abusing illicit drugs&#xD;
&#xD;
         17. Subject is currently abusing prescription drugs&#xD;
&#xD;
         18. Subject is currently abusing alcohol&#xD;
&#xD;
         19. Subject has elective surgery planned that requires general anaesthesia during the&#xD;
             course of the study&#xD;
&#xD;
         20. Subject is a shift worker with working hours between 10pm and 8am&#xD;
&#xD;
         21. Subject has a sickle cell disease, haemoglobinopathy; or has received red blood cell&#xD;
             transfusion or erythropoietin within 3 months prior to time of screening&#xD;
&#xD;
         22. Subject plans to receive red blood cell transfusion or erythropoietin over the course&#xD;
             of study participation&#xD;
&#xD;
         23. Subject diagnosed with current eating disorder such as anorexia or bulimia&#xD;
&#xD;
         24. Subject plans to use significant quantity of herbal preparations (use of over the&#xD;
             counter herbal preparation for 30 consecutive days or longer period during the study)&#xD;
             or significant quantity of vitamin supplements (four times the recommended daily&#xD;
             allowance used for 30 consecutive days or longer period during the study) known to&#xD;
             affect glucose metabolism and/or blood glucose levels during the course of their&#xD;
             participation in the study&#xD;
&#xD;
         25. Subject not proficient in English (UK), or German (Austria)&#xD;
&#xD;
        Additional exclusion criteria specific for Austria&#xD;
&#xD;
          1. Positive results on urine drug screen (amphetamines/metamphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates).&#xD;
&#xD;
          2. Positive alcohol breath test.&#xD;
&#xD;
          3. Positive reaction to any of the following tests: hepatitis B surface (HBs) antigen,&#xD;
             anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus (HIV)&#xD;
             1 antibodies, anti-HIV2 antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Hovorka, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Dr Roman Hovorka</investigator_full_name>
    <investigator_title>Chief Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. To gain access, data requestors will need to sign a data access agreement.&#xD;
Fully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. To gain access, data requestors will need to sign a data access agreement.</ipd_time_frame>
    <ipd_access_criteria>Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

